Peptide Vaccine for Advanced ALK+ Lung Cancer
This study is testing a peptide vaccine to see if it can help prevent or delay advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) from becoming resistant to current ALK-targeted treatments. You may be able to join if you have stage IV NSCLC or recurrent NSCLC that has an ALK gene change (fusion protein expression). Researchers will be looking at how safe the peptide vaccine is and if it creates an immune response in your body. The study is currently unclear about its recruitment status and plans to enroll 12 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. The study aims to enroll 12 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 2 years to measure treatment-related side effects and immune responses.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Vincent Lam, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of treatment-related adverse eventsUp to 2 years
The safety of administering the ALK peptide vaccine will be assessed by the occurrence of the following adverse events: * Grade 3 or above drug-related toxicities * Drug-related toxicity by grade * Vaccine site reactions after vaccine injections * Immune-related adverse events (AEs) * Unacceptable toxicities * Treatment-emergent changes from normal to abnormal values in key laboratory parameters
- Vaccine-specific immune responseUp to 2 years
Vaccine-specific response will be evaluated by the fold change in interferon-producing mutant-ALK-specific CD8 and CD4 T cells in the peripheral blood.